Lyell Immunopharma Appoints Mark Bachleda to Board of Directors

Strategic Insights -

Lyell Immunopharma, a biotechnology company focused on cancer immunotherapy, has made a significant move by increasing its Board of Directors to eight members and appointing Mark Bachleda as a Class I director. This development comes with Dr. Bachleda's term set to expire in 2028, aligning with the Company's annual meeting of stockholders. As part of his compensation, Dr. Bachleda will receive an annual cash retainer, an initial equity grant, and annual equity grants, as outlined in the Non-Employee Director Compensation Policy. The Company has also entered into a standard indemnification agreement with Dr. Bachleda, as previously filed with the SEC.

Key Takeaways:

  • Lyell Immunopharma has increased its Board of Directors from seven to eight members.
  • Mark Bachleda, Pharm.D., M.B.A., has been appointed as a Class I director, with a term set to expire in 2028.
  • Dr. Bachleda's compensation package includes an annual cash retainer, an initial equity grant, and annual equity grants.
  • The Company has entered into a standard indemnification agreement with Dr. Bachleda.
  • Details regarding the appointment and compensation package were outlined in the Company's Quarterly Report on Form 10-Q and Registration Statement on Form S-1.

Statistics:

  • Lyell Immunopharma Board of Directors is now comprised of eight members.
  • Mark Bachleda's term as a Class I director expires in 2028.
  • The Company's standard indemnification agreement with Dr. Bachleda was previously filed on May 25, 2021.
  • Dr. Bachleda's compensation package includes an annual cash retainer, an initial equity grant, and annual equity grants, adjusted for the 1-for-20 reverse stock split.
  • company's standard indemnification agreement with Dr. Bachleda.

Sources:

  • Form 8-K (Current Report) filed with the U.S. Securities and Exchange Commission on June 9, 2025.
  • Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.
  • Registration Statement on Form S-1 (No. 333-256470) filed with the SEC on May 25, 2021.